Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Completed · Phase 2

Conditions studied: Pandemic H5N1 Influenza

In brief

Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell Culture Derived Influenza Vaccine in Adult Subjects.

Key facts

Study ID

NCT01776541

Run by

Novartis Vaccines

People needed

979

Starts

2013-01-01

Expected to finish

2014-05-01

Last updated by the study team

2015-02-03

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult subjects 18 to 64 years of age,
• Individuals willing to provide written informed consent,
• Individuals in good health,
• Individuals willing to allow for their serum samples to be stored beyond the study period.

You may not qualify if…

• Individuals not able to understand and follow study procedures,
• History of any significant illness,
• History of any chronic medical condition or progressive disease,
• Presence of medically significant cancer,
• Known or suspected impairment/alteration of immune function,
• Presence of any progressive or severe neurologic disorder,
• Presence of any bleeding disorders or conditions that prolongs bleeding time,
• History of allergy to vaccine components,
• Receipt of any other investigational product within 30 days prior to entry into the study,
• History of previous H5N1 vaccination,
• Receipt of any other type of seasonal vaccination within 2 months prior to entry into the study,
• Receipt of any other vaccine within 2 weeks prior to entry into the study
• Body temperature ≥38°C.0 (≥100.4° F) and/or acute illness within 3 days of intended study vaccination,
• Pregnant or breast feeding,
• Females of childbearing potential refusing to use acceptable method of birth control,
• Body mass index (BMI) ≥ 35 kg/m2,
• History of drug or alcohol abuse,
• Any planned surgery during study period,
• Individuals conducting the study and their immediate family members,
• Individuals with behavioral or cognitive impairment or psychiatric diseases.

Where it is running

• 1 Miami Research Associates — Miami, Florida, United States
• 2 Mercy Health Research — St Louis, Missouri, United States
• 3 Saint Louis University — St Louis, Missouri, United States
• 4 Benchmark Medical Research — Austin, Texas, United States
• 48 Hunter Clinical Research — Newcastle, New South Wales, Australia
• 46 CMAX — Adelaide, South Australia, Australia
• 47 Linear Clinical Research — Nedlands, Western Australia, Australia
• 80 Faculty of Tropical Medicine — Bangkok, Thailand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.